iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in Geneva, Switzerland. The clinical and translational data from the dose escalation portion of A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients, will be presented as mini oral presentations. Preclinical data from inupadenant will be presented in the poster session. Mini Oral Presentation DetailsTitle: The A2AR Antagonist Inupadenant Promotes Humoral Responses in PatientsAbstract Number
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.MarketBeat
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.MarketBeat
- iTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.MarketBeat
ITOS
Earnings
- 11/12/24 - Beat
ITOS
Sec Filings
- 11/21/24 - Form SC
- 11/19/24 - Form 4
- 11/19/24 - Form SC
- ITOS's page on the SEC website